Back to top

Image: Bigstock

Compared to Estimates, GE HealthCare (GEHC) Q3 Earnings: A Look at Key Metrics

Read MoreHide Full Article

For the quarter ended September 2026, GE HealthCare Technologies (GEHC - Free Report) reported revenue of $5.51 billion, up 7.2% over the same period last year. EPS came in at $1.34, compared to $1.07 in the year-ago quarter.

The reported revenue represents a surprise of +2.87% over the Zacks Consensus Estimate of $5.36 billion. With the consensus EPS estimate being $1.21, the EPS surprise was +10.74%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how GE HealthCare performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
  • Revenues- PCS (Patient Care Solutions): $793 million compared to the $708.25 million average estimate based on three analysts. The reported number represents a change of +8.5% year over year.
  • Revenues- Other: $2 million versus $11.3 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -86.7% change.
  • Revenues- PDx (Pharmaceutical Diagnostics): $846 million compared to the $818.86 million average estimate based on three analysts. The reported number represents a change of +13% year over year.
  • Segment EBIT- PDx (Pharmaceutical Diagnostics): $253 million versus $251.17 million estimated by three analysts on average.
  • Segment EBIT- PCS (Patient Care Solutions): $68 million versus $36.89 million estimated by three analysts on average.

View all Key Company Metrics for GE HealthCare here>>>

Shares of GE HealthCare have returned +7% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Published in